The impact of bone marrow micrometastases on metastatic disease-free survival in patients with colorectal carcinoma.
AffiliationDepartment of Academic Surgery, Cork University Hospital, Wilton, Cork, Ireland.
Aged, 80 and over
Antineoplastic Agents/therapeutic use
Bone Marrow Examination
Bone Marrow Neoplasms/pathology/*secondary
Predictive Value of Tests
MetadataShow full item record
CitationColorectal Dis. 2005 Jul;7(4):406-9.
JournalColorectal disease : the official journal of the Association of Coloproctology of, Great Britain and Ireland
AbstractAIMS: The biological relevance of bone marrow micrometastases (BMM) in colorectal cancer remains unknown. Here, we investigate their nature by examining the impact of the presence of BMM on metastatic disease-free survival in a cohort of patients with this disease. METHODS: Sixty-three consecutive patients undergoing surgery for colorectal cancer of any stage were studied after approval of the study protocol by the local ethics committee and with full individual informed consent. All had bilateral iliac crest bone marrow aspirates prior to operation. Aspirates were then examined for the presence of aberrant cytokeratin-18-positive cells by a blinded observer using both flow cytometric and APAAP immunohistochemical techniques. RESULTS: Mean follow-up after surgery was 4.6 years (range 1.9-6.9) for those without hepatic metastases at diagnosis. Seven of 34 patients with Dukes' stage A or B developed metastatic disease after a mean interval of 4.7 years (range 3.8-6.8). However, only 2 of these patients demonstrated BMM at the time of surgery. Nine of 15 patients with Dukes' C carcinoma at the time of surgery subsequently developed metastases after a mean interval of 4.4 years (range 1.9-6.9). Again, only two of these patients had BMM detectable initially. In only three of the 14 patients known to have metastases at the time of operation (i.e. Dukes''D' disease) were BMM found. CONCLUSION: The presence of BMM as detected by this methodology was not predictive of tumour recurrence or metastasis. This study does not support the consideration of adjuvant therapy based on the presence of BMM at a single pre-operative time point in patients with colorectal cancer.
- Cyclooxygenase-2 expression in primary human colorectal cancers and bone marrow micrometastases.
- Authors: Sheehan KM, Cahill RA, McGreal G, Steele C, Byrne MF, Kirwan WO, Kay EW, Fitzgerald DJ, Redmond HP, Murray FE
- Issue date: 2004 Jun
- Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
- Authors: Saha S, Ali S, Ghanem M, Soni M, Wiese D, Arora M, Singh T, Iddings D
- Issue date: 2009 Feb
- Clinical significance of bone marrow microinvolvement in nonsmall cell lung carcinoma.
- Authors: Hsu CP, Shai SE, Hsia JY, Chen CY
- Issue date: 2004 Feb 15
- The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival.
- Authors: Murphy J, O'Sullivan GC, Lee G, Madden M, Shanahan F, Collins JK, Talbot IC
- Issue date: 2000 Dec
- Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
- Authors: Pfannschmidt J, Bade S, Hoheisel J, Muley T, Dienemann H, Herpel E
- Issue date: 2009 Oct